Visit other SMART + STRONG sites:
AIDSMEDSREAL HEALTHTU SALUD
Subscribe to:
POZ magazine
E-newsletters
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2008

Web Exclusives

My Future at NMAC

Puckering Up for AIDS Awareness

AIDSmeds in San Francisco: Highlights from CROI 2010

» More

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

10 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

April 25, 2008

Treatment Failure: Symptoms Matter Too

Symptoms of failing health are nearly as effective as viral loads or CD4 counts in determining if an antiretroviral (ARV) treatment regimen has stopped working and needs to be switched, according to new research published in The Lancet and reported by AIDSmap. These findings have important implications in developing countries, where shortages of viral load and CD4 tests are delaying the rollout of much needed ARV therapy. 

Using data from a number of cohort studies, Andrew Phillips, MD, of the Royal Free and University College Medical School in London, and his colleagues designed a computerized system to predict short- and long-term survival in people switching from a first to a second ARV regimen. They asked the system to predict survival if people switched following a viral load result above 500 copies, a CD4 drop of at least 50 percent from the highest measure after starting treatment, or based on a set of HIV-related symptoms maintained by the World Health Organization (WHO). Survival five years after a switch was 82 to 83 percent for each of the three models. It was only after 20 years where switching due to symptoms performed significantly less well than CD4 count or viral load.

The authors concede that computer simulations are not equal to clinical studies, and that their results stand in contrast to a clinical study conducted in Uganda in 2003 and 2004. However, they still conclude that these data support arguments favoring the distribution of ARV therapy in countries that do not have access to the viral load or CD4 tests that are typically used as a component of follow-up care in industrialized nations.

Search: CD4, viral load, Royal Free, Andrew, Phillips, Uganda, WHO


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

         


[Go to top]

Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Community
Advocacy
Job Listings
Events Calendar
Starting Treatment
My Cool Tools


    AloneInNYC
    New york city
    New York


    nameless23
    Seattle
    Washington


    sunsoldier
    Hartford
    Connecticut


    aztekcasper
    Chi-town
    Illinois
Click here to join POZ Personals!
Talk to Us
Poll
Question: Do you agree that laws criminalizing homosexuality, drug use and sex work increase new HIV cases globally?
Yes
No

Survey
Peace of Mind

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy